Stockreport

IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025

Imunon, Inc.  (IMNN) 
PDF LAWRENCEVILLE, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy [Read more]